Harlan Waksal

Director, Eloxx Pharmaceuticals, Inc.

Companies

Lyra Therapeutics, Inc.Chair Feb 18, 2022 to now¹
Freenome, Inc.Board member Jun 11, 2024 to Jun 11, 2024²
Kadmon Holdings, Inc.Board member Jul 26, 2016 to Nov 9, 2021³
Kadmon Holdings, Inc.Chief executive officer Jul 26, 2016 to Nov 9, 2021³
Kadmon Holdings, Inc.President Jul 26, 2016 to Nov 9, 2021³
Eloxx Pharmaceuticals, Inc.Board member Nov 3, 2008 to Nov 23, 2015⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Freenome, Inc. FRNM30,000 shares⁵$369.8K at $12.32Jul 20, 2026
Lyra Therapeutics, Inc.536,966 shares⁶Mar 18, 2024
Kadmon Holdings, Inc.0 shares⁷Nov 9, 2021

As of each latest filing. The line shows shares held over time.

Recent filings

Jul 20, 2026Converted 30,000 shares of Freenome, Inc.⁵
Mar 18, 2024Granted 275,000 shares of Lyra Therapeutics, Inc.⁶
Nov 10, 2023Bought 25,000 shares at $2.96 of Lyra Therapeutics, Inc.⁸
Apr 12, 2022Bought 236,966 shares at $4.22 of Lyra Therapeutics, Inc.⁹
Nov 9, 2021Returned to company 177,945 shares at $9.50 of Kadmon Holdings, Inc.⁷

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARLyra Therapeutics, Inc., Chair
2
SEC EDGARFreenome, Inc., Board member
3
SEC EDGARKadmon Holdings, Inc., Board member
4
SEC EDGAREloxx Pharmaceuticals, Inc., Board member
5
SEC EDGARFreenome, Inc. shares after the filing of Jul 20, 2026
6
SEC EDGARLyra Therapeutics, Inc. shares after the filing of Mar 18, 2024
7
SEC EDGARKadmon Holdings, Inc. shares after the filing of Nov 9, 2021
8
SEC EDGARForm 4 filed Nov 13, 2023
9
SEC EDGARForm 4 filed Apr 13, 2022